BiologicalDrug
Clazakizumab clinical trials
Also written BMS-945429 and ALD518.
Keep track of what changes. Save the clazakizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
19 studies that test it; most in 2020 (4)
| Year | Studies |
|---|---|
| 2008 | 2 |
| 2011 | 3 |
| 2012 | 3 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 4 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 9
CSL Behring (9) · Stanley Jordan, MD (2) · Anne B. Newman (1) · University of North Carolina, Chapel Hill (1) · Cedars-Sinai Medical Center (1) · NYU Langone Health (1) · Medical University of Vienna (1) · Eli Lilly and Company (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses clazakizumab is read from its arms, and is right about nine times in ten.
Testing it · 19
- A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular EventRecruitingPhase 2Eli Lilly and CompanyNCT07783802Written as Clazakizumab
- Improving Physical Function in Older Adults Using an Anti-inflammation Drug: The RIGHT StudyCompletedPhase 2Anne B. NewmanNCT05727384Written as Clazakizumab
- PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network StudyCompletedPhase 2University of North Carolina, Chapel HillNCT04129931Written as Clazakizumab
- Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant RecipientsTerminatedPhase 3CSL BehringNCT03744910Written as Clazakizumab
- Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney TransplantCompletedPhase 1/2Stanley Jordan, MDNCT03380377Written as Clazakizumab
- Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal TransplantActive, not recruitingPhase 1/2Stanley Jordan, MDNCT03380962Written as Clazakizumab
- Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19)CompletedPhase 2Cedars-Sinai Medical CenterNCT04348500Written as Clazakizumab
- A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 InfectionCompletedPhase 2NYU Langone HealthNCT04343989Written as Clazakizumab 25 mg
- Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 InfectionTerminatedPhase 2Columbia UniversityNCT04381052Written as Clazakizumab
- Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to MethotrexateCompletedPhase 2CSL BehringNCT01373151Written as BMS-945429
- Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's DiseaseTerminatedPhase 2CSL BehringNCT01545050Written as BMS-945429
- Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) TherapyCompletedPhase 2CSL BehringNCT01490450Written as BMS-945429
- Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid ArthritisCompletedPhase 2CSL BehringNCT02015520Written as Clazakizumab
- Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer SubjectsTerminatedPhase 2CSL BehringNCT01403064Written as ALD518
- Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD)TerminatedPhase 1/2CSL BehringNCT01530256Written as ALD518
- A Pilot Trial of Clazakizumab in Late ABMRCompletedPhase 2Medical University of ViennaNCT03444103Written as Clazakizumab / Clazakizumab
- Clazakizumab vs. Placebo - COVID-19 InfectionStatus unknownPhase 2The Methodist Hospital Research InstituteNCT04494724Written as Clazakizumab
- Safety, Efficacy and Pharmacokinetics Study of ALD518 in Patients With Active Rheumatoid ArthritisCompletedPhase 2CSL BehringNCT00867516Written as ALD518
- Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and CachexiaCompletedPhase 2CSL BehringNCT00866970Written as ALD518
Codes
What other systems call clazakizumab · ClinicalTrials.gg INT000402
- MeSH (NLM) C000604955clazakizumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 4S38Z8RA9OCLAZAKIZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q3601001clazakizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C82359ClazakizumabOne source FDA
- DrugBank DB12849One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000604955 | clazakizumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 4S38Z8RA9O | CLAZAKIZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q3601001 | clazakizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C82359 | Clazakizumab | One source FDA |
| DrugBank | DB12849 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.